Home › Research › Laboratory science
Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic
Roveta F, Pizzini FB, Natale V, Scheffler M, Garibotto V, Mendes AJ, Wang C, Lathuiliere A, Chicherio C, Rainero I, Frisoni GB, Ribaldi F. Neurology, 2025-12-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objectives Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a neurodegenerative condition often overlapping clinically with Alzheimer disease (AD). No established in vivo biomarkers exist for LATE. The amygdalar atrophy scale (AAS) is a visual MRI rating tool scoring the amygdala as AAS 0 (no atrophy), AAS 1 (mild-to-moderate atrophy), or AAS 2 (severe atrophy) and is associated with TDP-43 neuropathology in limbic regions. This study describes the clinical, neuroimaging, and longitudinal cognitive profiles of individuals classified using a proposed framework that combines the AAS with established AD biomarkers. Methods This retrospective study included individuals attending the Geneva Memory Center (2014-2022) who underwent T1-weighted MRI, as well as clinical and neuropsychological assessments. Participants were categorized with an etiologic grouping defined as No-AD/No-LATE (AAS 0 , negative AD biomarkers), AD (AAS 0 , positive AD biomarkers), LATE (AAS 1-2 , negative AD biomarkers), or AD/LATE (AAS 1-2 , positive AD biomarkers). Group differences were compared using Kruskal-Wallis or χ 2 tests. Differences in MRI brain volumes and cortical thickness between groups were examined with analysis of covariance. Cognitive trajectories using Mini-Mental State Examination (MMSE) scores over 30 months were estimated with linear mixed-effects models accounting for baseline age and education. Results The analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female). The No-AD/No-LATE group exhibited the highest MMSE scores (N = 181, 27.9 ± 2.2), outperforming AD (N = 146, 24.2 ± 4.9), LATE (N = 36, 26.2 ± 3.2), and AD/LATE (N = 106, 22.5 ± 5.3) groups ( p p p = 0.813), whereas both AD (β = -0.136, 95% CI -0.184 to -0.088, p p Discussion Patients identified as LATE by the integration of AAS with AD biomarkers had generally mild amnestic cognitive impairment, significant limbic atrophy, and slow decline over time, all features consistent with previous autopsy series. Moreover, AD/LATE cases were more impaired than those with LATE or AD alone. Prospective and neuropathologic validation is warranted.
What this study adds
Evidence grade: Early
This is a follow-up (cohort) study of 469 participants. This study describes a visual MRI rating of amygdala shrinkage used together with existing Alzheimer's biomarkers to sort memory clinic patients into groups, including one thought to have LATE. Reported effect size: MMSE slope over 30 months: -0.010 (LATE) vs -0.136 (AD) and -0.139 (AD/LATE).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Roveta, F., Pizzini, F. B., Natale, V., Scheffler, M., Garibotto, V., Mendes, A. J., et al. (2026). Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic. Neurology. https://doi.org/10.1212/WNL.0000000000214477
Vancouver
Roveta F, Pizzini FB, Natale V, Scheffler M, Garibotto V, Mendes AJ, et al. Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic. Neurology. 2026. doi:10.1212/WNL.0000000000214477. PMID: 41428981.
BibTeX
@article{roveta2026-41428981,
author = {Roveta, F. and Pizzini, F. B. and Natale, V. and Scheffler, M. and Garibotto, V. and Mendes, A. J. and Wang, C. and Lathuiliere, A. and Chicherio, C. and Rainero, I. and Frisoni, G. B. and Ribaldi, F.},
title = {{Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic}},
journal = {Neurology},
year = {2026},
doi = {10.1212/WNL.0000000000214477},
pmid = {41428981},
url = {https://doi.org/10.1212/WNL.0000000000214477}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 12 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The amygdalar atrophy scale (AAS) is a visual MRI rating tool scoring the amygdala as AAS 0 (no atrophy), AAS 1 (mild-to-moderate atrophy), or AAS 2 (severe atrophy) and is associated with TDP-43 neuropathology in limbic regions.
- Results The analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female).
- The No-AD/No-LATE group exhibited the highest MMSE scores (N = 181, 27.9 ± 2.2), outperforming AD (N = 146, 24.2 ± 4.9), LATE (N = 36, 26.2 ± 3.2), and AD/LATE (N = 106, 22.5 ± 5.3) groups ( p < 0.001).
Why it matters
This study describes a visual MRI rating of amygdala shrinkage used together with existing Alzheimer's biomarkers to sort memory clinic patients into groups, including one thought to have LATE. It is a retrospective description of patient profiles, not a treatment or cure, and it does not show that this approach changes outcomes.
Study details
- Study designcohort
- Participants469
- Effect sizeMMSE slope over 30 months: -0.010 (LATE) vs -0.136 (AD) and -0.139 (AD/LATE)
- Evidence strengthEarly
Limitations
Retrospective single-centre design with investigations determined by routine practice, creating selection bias and possibly affecting internal validity; the LATE group was small (n = 36), lowering power; and other causes of amygdalar atrophy such as alpha-synuclein or frontotemporal TDP-43 pathology were not evaluated for lack of biomarkers or autopsy confirmation.
How this study scored 56/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 55 of the 98 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 469 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Federica Ribaldi: h-index 25 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Geneva: institution h-index 1,049 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41428981) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 55 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 98 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/WNL.0000000000214477
- PubMed: 41428981
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Laboratory science from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.